MAIA Biotechnology, Inc. 8-K

What Happened MAIA Biotechnology, Inc. filed a Form 8-K on April 8, 2026 and issued a press release stating that it expects a recent $33 million capital raise to fully fund its ongoing pivotal Phase 3 trial of ateganosine, a telomere‑targeting anticancer therapy. The press release is attached as Exhibit 99.1 to the filing. The company also included standard forward‑looking statement language and cautions about risks and uncertainties.

Key Details

• Filing date: April 8, 2026; press release attached as Exhibit 99.1.
• Reported amount raised: $33 million (described as expected to fully fund the pivotal Phase 3 trial).
• Drug referenced: ateganosine (telomere‑targeting anticancer therapy) currently in a Phase 3 trial.
• Filing reiterates forward‑looking statement risks, including the funding status for the Phase 3 trial among other clinical, regulatory, manufacturing and commercial risks.

Why It Matters The company states the $33 million raise is expected to cover the costs of its pivotal Phase 3 program for ateganosine, addressing the specific funding risk highlighted in the filing. For investors, this announcement is material because it relates directly to the financing and continuation of the company’s lead clinical program; however, the company’s statements are forward‑looking and subject to the risks and uncertainties described in the filing.